Top ▲


Click here for help

Target id: 1326

Nomenclature: CYP2C9

Family: CYP2 family: drug metabolising subset

Gene and Protein Information Click here for help
Species TM AA Chromosomal Location Gene Symbol Gene Name Reference
Human - 490 10q23.33 CYP2C9 cytochrome P450 family 2 subfamily C member 9
Previous and Unofficial Names Click here for help
(R)-Limonene 6-monooxygenase | (S)-limonene 6-monooxygenase | (S)-limonene 7-monooxygenase | S-mephenytoin 4-hydroxylase | CYP2C10 | cytochrome P450, subfamily IIC (mephenytoin 4-hydroxylase), polypeptide 9 | cytochrome P450, family 2, subfamily C, polypeptide 9
Database Links Click here for help
ChEMBL Target
Ensembl Gene
Entrez Gene
Human Protein Atlas
KEGG Enzyme
Enzyme Reaction Click here for help
EC Number:
Description Reaction Reference
(S)-limonene + [reduced NADPH--hemoprotein reductase] + O(2) <=> (-)-trans-carveol + [oxidized NADPH--hemoprotein reductase] + H(2)O
Substrates and Reaction Kinetics Click here for help
Substrate Sp. Property Value Units Standard property Standard value Assay description Assay conditions Comments Reference
sulfaphenazole Hs - -

Download all structure-activity data for this target as a CSV file go icon to follow link

Key to terms and symbols View all chemical structures Click column headers to sort
Ligand Sp. Action Value Parameter Reference
compound 3 [PMID: 18255300] Small molecule or natural product Hs Inhibition 8.4 pKi 5
pKi 8.4 (Ki 4.2x10-9 M) [5]
sulfaphenazole Small molecule or natural product Hs Inhibition 6.5 pKi 1,4
pKi 6.5 (Ki 3x10-7 M) [1,4]
compound 51 [Crosignani et al., 2011] Small molecule or natural product Click here for species-specific activity table Hs Inhibition 6.7 pIC50 2
pIC50 6.7 (IC50 2x10-7 M) [2]
voxelotor Small molecule or natural product Approved drug Click here for species-specific activity table Hs Inhibition 5.1 pIC50 3
pIC50 5.1 (IC50 8.5x10-6 M) [3]
Description: Measuring inhibition of CYP2C9 activity using tolbutamide as substrate.
noscapine Small molecule or natural product Ligand has a PDB structure N/A Inhibition - -
View species-specific inhibitor tables
General Comments
Cytochrome P450 2C9 (CYP2C9) is one of the three major drug metabolizing cytochrome P450 enzymes in human liver.


Show »

1. Bourrié M, Meunier V, Berger Y, Fabre G. (1996) Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes. J Pharmacol Exp Ther, 277 (1): 321-32. [PMID:8613937]

2. Crosignani S, Jorand-Lebrun C, Campbell G, Prêtre A, Grippi-Vallotton T, Quattropani A, Bouscary-Desforges G, Bombrun A, Missotten M, Humbert Y et al.. (2011) Discovery of a Novel Series of CRTH2 (DP2) Receptor Antagonists Devoid of Carboxylic Acids. ACS Med Chem Lett, 2 (12): 938-42. [PMID:24900284]

3. Metcalf B, Chuang C, Dufu K, Patel MP, Silva-Garcia A, Johnson C, Lu Q, Partridge JR, Patskovska L, Patskovsky Y et al.. (2017) Discovery of GBT440, an Orally Bioavailable R-State Stabilizer of Sickle Cell Hemoglobin. ACS Med Chem Lett, 8 (3): 321-326. [PMID:28337324]

4. Miners JO, Smith KJ, Robson RA, McManus ME, Veronese ME, Birkett DJ. (1988) Tolbutamide hydroxylation by human liver microsomes. Kinetic characterisation and relationship to other cytochrome P-450 dependent xenobiotic oxidations. Biochem Pharmacol, 37 (6): 1137-44. [PMID:3355588]

5. Peng CC, Rushmore T, Crouch GJ, Jones JP. (2008) Modeling and synthesis of novel tight-binding inhibitors of cytochrome P450 2C9. Bioorg Med Chem, 16 (7): 4064-74. [PMID:18255300]


Show »

How to cite this page